• Can Fate Therapeutics (NASDAQ:FATE) Boost Healthcare Stocks? Kalkine Media Fri, 10 Jul 2026 08:36:00 GMT
• Fate Therapeutics Gets FDA Clearance for FT839 Autoimmune CAR-T Therapy The Clinical Trial Vanguard Fri, 10 Jul 2026 06:48:45 GMT
• Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 Moomoo Thu, 09 Jul 2026 21:45:36 GMT
• FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials Stocktwits Thu, 09 Jul 2026 20:52:00 GMT
• Fate Therapeutics Wins FDA IND Clearance for FT839, a Dual-CAR T-Cell Therapy for Autoimmune Disease BioPharm International Thu, 09 Jul 2026 20:30:27 GMT
• Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 marketscreener.com Thu, 09 Jul 2026 18:51:35 GMT
• Fate Therapeutics gains after IND clearance (FATE:NASDAQ) Seeking Alpha Thu, 09 Jul 2026 14:38:06 GMT
• Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease Fierce Biotech Thu, 09 Jul 2026 14:24:29 GMT
• fate therapeutics announces fda clearance of ind for ft839 dual-car t cell therapy in autoimmune disease Quiver Quantitative Thu, 09 Jul 2026 12:44:00 GMT
• Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate GlobeNewswire Thu, 09 Jul 2026 12:30:00 GMT
• FDA clears Fate Therapeutics' FT839 for autoimmune trial push Stock Titan Thu, 09 Jul 2026 12:30:00 GMT
• Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade) Seeking Alpha Wed, 08 Jul 2026 15:54:44 GMT
• Fate Therapeutics looks to its pipeline as investors weigh long-term prospects AD HOC NEWS Tue, 07 Jul 2026 20:12:33 GMT
• Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54 simplywall.st Mon, 06 Jul 2026 16:10:38 GMT
• Fate Therapeutics to present FT819 data at stem cell meeting Investing.com Mon, 06 Jul 2026 13:36:25 GMT
• fate therapeutics announces preliminary ft819 data in systemic sclerosis for isscr 2026 presentation Quiver Quantitative Mon, 06 Jul 2026 12:44:00 GMT
• Fate Therapeutics to Present Preliminary Clinical Data of GlobeNewswire Mon, 06 Jul 2026 12:30:00 GMT
• Fate Therapeutics to show early FT819 data in systemic sclerosis Stock Titan Mon, 06 Jul 2026 12:30:00 GMT
• fate therapeutics (fate) slides to $2.92 as support levels come into focus - volume gap dars.gov.et Sun, 05 Jul 2026 17:35:25 GMT
• Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects AD HOC NEWS Fri, 03 Jul 2026 17:38:51 GMT
• fate therapeutics lines up four investor conferences in q3 Stock Titan Wed, 01 Jul 2026 20:05:00 GMT
• Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences Yahoo Finance Wed, 01 Jul 2026 07:00:00 GMT
• A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs Sahm Tue, 30 Jun 2026 07:00:00 GMT
• Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index marketscreener.com Mon, 29 Jun 2026 18:43:36 GMT
• Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from Russell Small Cap Completeness Index marketscreener.com Sun, 28 Jun 2026 22:00:00 GMT
• fate therapeutics stock pops as ft836 cancer data impress traders StocksToTrade Sun, 28 Jun 2026 12:37:00 GMT
• Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index marketscreener.com Sun, 28 Jun 2026 07:00:00 GMT
• fate therapeutics inc (fate) stock price, quote, news & history Benzinga Fri, 26 Jun 2026 23:10:00 GMT
• Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move AD HOC NEWS Fri, 26 Jun 2026 18:04:36 GMT
• fate therapeutics inc (fate) valuation: pe, pb & fair value analysis TradingKey Fri, 26 Jun 2026 10:18:42 GMT
• fate therapeutics, inc. actuals & estimates (tradegate:f6t) TradingView Fri, 26 Jun 2026 07:01:57 GMT
• Fate Therapeutics, Inc. Actuals & Estimates (NASDAQ:FATE) TradingView Fri, 26 Jun 2026 03:13:22 GMT
• price to earnings forward of fate therapeutics, inc. – nasdaq:fate TradingView Thu, 25 Jun 2026 23:49:52 GMT
• Price to book forward of Fate Therapeutics, Inc. – NASDAQ:FATE TradingView Thu, 25 Jun 2026 23:48:25 GMT
• price to sales forward of fate therapeutics, inc. – nasdaq:fate TradingView Thu, 25 Jun 2026 23:27:33 GMT
• h.c. wainwright maintains fate therapeutics(fate.us) with buy rating, maintains target price $7 Moomoo Wed, 24 Jun 2026 11:33:00 GMT
• Fate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE) Seeking Alpha Wed, 24 Jun 2026 07:00:00 GMT
• fate therapeutics inc (fate) financial health: profitability & balance sheet analysis TradingKey Wed, 24 Jun 2026 07:00:00 GMT
• fate q1 2026 earnings: narrower-than-expected loss highlights operational discipline - revenue growth outlook dars.gov.et Tue, 23 Jun 2026 07:00:00 GMT
• fate therapeutics inc (fate) technical analysis: support, resistance, indicators & moving averages TradingKey Tue, 23 Jun 2026 07:00:00 GMT
• fate therapeutics inc (fate) earnings forecast: future eps & revenue growth estimates TradingKey Tue, 23 Jun 2026 07:00:00 GMT
• fate therapeutics inc (fate) valuation: pe, pb & fair value analysis TradingKey Tue, 23 Jun 2026 07:00:00 GMT
• fate therapeutics inc (fate) financial health: profitability & balance sheet analysis TradingKey Tue, 23 Jun 2026 07:00:00 GMT
• fate therapeutics inc (fate) financial health: profitability & balance sheet analysis TradingKey Thu, 18 Jun 2026 09:48:51 GMT
• Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages TradingKey Thu, 18 Jun 2026 09:25:23 GMT
• fate therapeutics inc (fate) risk assessment: volatility, financial risk & investment risk TradingKey Thu, 18 Jun 2026 09:23:31 GMT
• fate therapeutics inc (fate) valuation: pe, pb & fair value analysis TradingKey Thu, 18 Jun 2026 09:21:31 GMT
• fate therapeutics inc (fate) earnings forecast: future eps & revenue growth estimates TradingKey Thu, 18 Jun 2026 09:19:35 GMT
• fate therapeutics inc (fate) dividends & stock splits: historical payouts and event timeline TradingKey Thu, 18 Jun 2026 08:10:30 GMT
• fate therapeutics inc (fate) shareholder structure: major shareholders & institutional holdings TradingKey Thu, 18 Jun 2026 07:52:10 GMT
• fate therapeutics inc (fate) revenue breakdown: business segments, regional revenue & profit contribution TradingKey Thu, 18 Jun 2026 07:47:57 GMT
• fate therapeutics (fate) institutional ownership 2026 $fate MarketBeat Thu, 18 Jun 2026 07:00:00 GMT
• fate therapeutics shareholders back directors and governance plans The Globe and Mail Tue, 16 Jun 2026 21:28:00 GMT
• fate therapeutics inc (fate) earnings forecast: future eps & revenue growth estimates TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• fate's new gambit: a commercial titan to unlock cell therapy's future BriefGlance Mon, 15 Jun 2026 12:30:00 GMT
• Fate Therapeutics Appoints Laura Hamill to Board of Directors GlobeNewswire Mon, 15 Jun 2026 07:00:00 GMT
• Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE) Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• director yuan xu receives 87,900 fate therapeutics (fate) stock options at $2.06 Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• fate therapeutics (fate) director granted 87,900 stock options at $2.06 Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• fate therapeutics (nasdaq: fate) director awarded 87,900 stock options as equity pay Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• director laura hamill receives 175,800 fate therapeutics (fate) stock options Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• redmile director nominee awarded 87,900 fate therapeutics (fate) stock options Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• fate therapeutics inc stock (us3025491025): valuation focus as clinical-stage biotech trades near lo AD HOC NEWS Mon, 15 Jun 2026 07:00:00 GMT
• fate sec filings - fate therapeutic 10-k, 10-q, 8-k forms Stock Titan Thu, 11 Jun 2026 07:08:48 GMT
• H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT Yahoo Finance Wed, 10 Jun 2026 07:00:00 GMT
• Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 Moomoo Tue, 09 Jun 2026 07:00:00 GMT
• wall street analysts are bullish on top healthcare picks The Globe and Mail Tue, 09 Jun 2026 07:00:00 GMT
• h.c. wainwright maintains fate therapeutics(fate.us) with buy rating, maintains target price $7 富途牛牛 Tue, 09 Jun 2026 01:57:26 GMT
• fate reiterated by hc wainwright & co. -- price target maintained at $7.00 GuruFocus Mon, 08 Jun 2026 19:18:45 GMT
• h.c. wainwright reiterates fate therapeutics stock rating on sle data Investing.com Mon, 08 Jun 2026 07:00:00 GMT
• piper sandler maintains fate therapeutics(fate.us) with buy rating, maintains target price $6 Moomoo Fri, 05 Jun 2026 07:00:00 GMT
• fate therapeutics advances off-the-shelf car t-cell therapies for autoimmune diseases and cancer – clinical pipeline and 2026 upda... Minichart Fri, 05 Jun 2026 03:59:00 GMT
• Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash TradingView Thu, 04 Jun 2026 07:00:00 GMT
• Fate Therapeutics presents autoimmune therapy data at EULAR Investing.com Thu, 04 Jun 2026 07:00:00 GMT
• fate therapeutics (nasdaq: fate) details ft819, ft836 data and cash runway into 2028 Stock Titan Thu, 04 Jun 2026 07:00:00 GMT
• small lupus trial tests off-the-shelf car t with same-day discharge Stock Titan Thu, 04 Jun 2026 07:00:00 GMT
• fate therapeutics reports new employee inducement awards under nasdaq listing rule 5635(c)(4) The Manila Times Wed, 03 Jun 2026 07:00:00 GMT
• CAR-T With Nine Engineered Edits Shrinks Colorectal Tumours CRISPR Medicine News Wed, 03 Jun 2026 05:21:03 GMT
• Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance Tue, 02 Jun 2026 07:00:00 GMT
• Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting Yahoo Finance Mon, 01 Jun 2026 07:00:00 GMT
• Off-the-shelf FT836 shrinks tumors in colorectal cancer without conditioning chemo Stock Titan Mon, 01 Jun 2026 07:00:00 GMT
• Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? Yahoo Finance Sat, 30 May 2026 07:00:00 GMT
• the $13 million company teaching the immune system to hunt cancer Quantisnow Fri, 29 May 2026 13:25:11 GMT
• fate therapeutics rallies 9.5% as fate stock breaks above key support level - stock buy zone dars.gov.et Wed, 27 May 2026 07:00:00 GMT
• fate therapeutics surges over 10% as biotech sector shows signs of life (fate) - rsi oversold picks dars.gov.et Wed, 27 May 2026 07:00:00 GMT
• h.c. wainwright maintains fate therapeutics(fate.us) with buy rating, maintains target price $7 Moomoo Tue, 26 May 2026 07:00:00 GMT
• fate therapeutics ceo bahram valamehr sells $54,482 in shares by investing.com Investing.com India Fri, 22 May 2026 20:35:09 GMT
• bofa securities maintains fate therapeutics(fate.us) with hold rating, raises target price to $2.2 Moomoo Fri, 22 May 2026 07:00:00 GMT
• fate stock price, quote & chart | fate therapeutics inc (nasdaq:fate) ChartMill Fri, 22 May 2026 07:00:00 GMT
• fate therapeutics to present car t-cell therapy data at medical conferences StreetInsider Thu, 21 May 2026 13:36:08 GMT
• Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares Investing.com Thu, 21 May 2026 07:00:00 GMT
• Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale Stock Titan Thu, 21 May 2026 07:00:00 GMT
• fate therapeutics announces presentations at 2026 asco and GlobeNewswire Thu, 21 May 2026 07:00:00 GMT
• fate therapeutics to present car t-cell data at medical conferences Investing.com Nigeria Thu, 21 May 2026 07:00:00 GMT
• off-the-shelf car t trials in cancer and autoimmune at 2026 asco, eular Stock Titan Thu, 21 May 2026 07:00:00 GMT
• fate therapeutics (fate) officer sells 25,590 shares in tax-related transaction Stock Titan Thu, 21 May 2026 07:00:00 GMT
• Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Investing News Network Wed, 20 May 2026 14:40:14 GMT
• jefferies initiates fate therapeutics stock with buy rating on autoimmune potential by investing.com Investing.com South Africa Wed, 20 May 2026 01:37:28 GMT
• jefferies initiates fate therapeutics(fate.us) with buy rating, announces target price $4 Moomoo Tue, 19 May 2026 19:31:00 GMT
• fate therapeutics (fate) reports q1 loss, misses revenue estimates MSN Tue, 19 May 2026 08:56:08 GMT
• jefferies initiates fate therapeutics stock with buy rating on autoimmune potential Investing.com Tue, 19 May 2026 07:00:00 GMT
• fate therapeutics (fate) reports q1 loss, misses revenue estimates MSN Sun, 17 May 2026 17:55:12 GMT
• fate therapeutics stock (us3025491025): biotech hopeful in focus after analyst targets and cash runw AD HOC NEWS Sun, 17 May 2026 07:00:00 GMT
• Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation simplywall.st Fri, 15 May 2026 07:00:00 GMT
• solid tumor treatment race heats up as multi-billion-dollar oncology market enters high-growth phase ChartMill Thu, 14 May 2026 13:00:39 GMT
• key facts: fate $174.8m; reclaim-ln dosing h2 2026; q1 loss $0.26 TradingView Thu, 14 May 2026 07:55:34 GMT
• fate therapeutics, inc. 2026 q1 10-q report: financials, risk factors, and key disclosures Minichart Thu, 14 May 2026 07:00:00 GMT
• fate therapeutics earnings beat by $0.02, revenue topped estimates Investing.com Australia Thu, 14 May 2026 07:00:00 GMT
• fate therapeutics, inc. 2026 q1 10-q report: financials, risk factors, and key disclosures Minichart Wed, 13 May 2026 16:40:00 GMT
• Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates Yahoo Finance Wed, 13 May 2026 07:00:00 GMT
• Fate Therapeutics 1Q 2026: Revenue $1.3M, EPS $(0.26) — 10-Q Summary TradingView Wed, 13 May 2026 07:00:00 GMT
• Fate Therapeutics reports Q1 2026 net loss $31.2M, cash and investments $174.8M; runway into 2028 TradingView Wed, 13 May 2026 07:00:00 GMT
• fate therapeutics earnings beat by $0.02, revenue topped estimates Investing.com Wed, 13 May 2026 07:00:00 GMT
• fate therapeutics q1 operating loss narrows, cash runway extended into 2028 TradingView Wed, 13 May 2026 07:00:00 GMT
• fate therapeutics reports q1 2026 financial results, advances ft819 and ft839 car t-cell trials with extended cash runway into 202... Minichart Wed, 13 May 2026 07:00:00 GMT
• fate therapeutics inc reports results for the quarter ended march 31 - earnings summary TradingView Wed, 13 May 2026 07:00:00 GMT
• fate therapeutics (fate) reports q1 loss, misses revenue estimates Yahoo Finance Wed, 13 May 2026 07:00:00 GMT
• needham maintains fate therapeutics(fate.us) with hold rating, announces target price $2.25 富途牛牛 Wed, 13 May 2026 07:00:00 GMT
• fate therapeutics (nasdaq: fate) trims q1 loss, extends cash runway and advances ft819 Stock Titan Wed, 13 May 2026 07:00:00 GMT
• lupus car-t without conditioning chemo advances as fate cuts costs Stock Titan Wed, 13 May 2026 07:00:00 GMT
• fate therapeutics (nasdaq: fate) narrows q1 2026 loss as r&d costs fall Stock Titan Wed, 13 May 2026 07:00:00 GMT
• fate sec filings - fate therapeutic 10-k, 10-q, 8-k forms Stock Titan Tue, 12 May 2026 12:48:48 GMT
• fate therapeutics presents car t-cell therapy data at asgct Investing.com UK Tue, 12 May 2026 09:07:46 GMT
• Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026 (NASDAQ:FATE) Seeking Alpha Tue, 12 May 2026 07:00:00 GMT
• Fate Therapeutics Showcases FT819 Clinical Activity in SLE GlobeNewswire Mon, 11 May 2026 07:00:00 GMT
Fate Therapeutics, Inc(NASDAQ:FATE) 
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, ...
Website: http://www.fatetherapeutics.com
Founded: 2007
Full Time Employees: 178
Sector: Healthcare
Industry: Biotechnology